Winner
Virtual Reality Revolution in Post-CAR-T Cell Infusion Management
Summary of work
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) is an orphan medicinal treatment developed for certain rare cancers. Cytokine Release Syndrome (CRS) and neurological side-effects are known complications of CAR-T cell therapy that may occur when the T-cells multiply and activate in the patient’s body, and require urgent and complex care.1,2
Synergy and Cassette supported Novartis in designing and creating an immersive virtual reality space in which HCPs can learn best practice in the management of CRS and practice the management of patients in a safe and repeatable scenario.
1.Schuster SJ, et al. Blood Adv 2020;4(7):1432–9.
2.Maude SL, et al. N Engl J Med 2018;378(5):439–48.
Judges’ comments
The judges were impressed by this compelling and innovative approach to education – virtual reality for CAR-T Cell infusion. We saw clear metrics and the impact and importance of support within this space was well evidenced. They had good insights about how VR helps learning in medical schools and the innovation was clear as a solution to enhance the effectiveness of education/skills training.
